Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system. The company advances a pipeline of THETA-enabled therapeutics with an initial focus on neurodegenerative disorders. Its lead product candidate is KRSA-028, an anti-amyloid beta antibody for the treatment of Alzheimer's disease, which combines the THETA platform with elements of anti-amyloid beta approaches and targets a clinically relevant form of amyloid beta designed to improve brain uptake while reducing effects on reticulocytes. The company is also advancing a pipeline of additional THETA-enabled therapies for other neurodegenerative diseases. Korsana Biosciences, Inc. was incorporated in 2024 and is based in Waltham, Massachusetts.
Frequently asked questions
What sector does KRSA (KRSA) operate in?
KRSA belongs to the Other sector and operates in the Biotechnology industry.
What is KRSA (KRSA) current stock price?
As of the latest data, KRSA stock price is $30.07, with a previous close of $32.09. KRSA lost -$2.02 in the last trading session, representing a -6.29% loss.
What is KRSA (KRSA) current market capitalization?
KRSA market cap is approximately 1.37 billion.
What is KRSA (KRSA) Earnings Per Share (EPS)?
The trailing EPS is -$7.07, and the forward EPS is -$3.56.
What is KRSA (KRSA) EBITDA?
KRSA EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -1.75 million.
Does KRSA (KRSA) pay dividends?
No. KRSA does not pay a dividend.
When is KRSA (KRSA) next earnings report?
KRSA is expected to release its next earnings report on September 30, 2026.
What is KRSA (KRSA) beta (volatility) score?
KRSA has a beta of 1.725, suggesting it is more volatile than the market.
